| Literature DB >> 30010625 |
Motoyuki Tsuda1, Akihisa Fukuda1, Nilotpal Roy2, Yukiko Hiramatsu1, Laura Leonhardt2, Nobuyuki Kakiuchi1,3, Kaja Hoyer3,4, Satoshi Ogawa1, Norihiro Goto1, Kozo Ikuta1, Yoshito Kimura1, Yoshihide Matsumoto1, Yutaka Takada1, Takuto Yoshioka1, Takahisa Maruno1, Yuichi Yamaga1, Grace E Kim5, Haruhiko Akiyama6, Seishi Ogawa3, Christopher V Wright7, Dieter Saur8, Kyoichi Takaori9, Shinji Uemoto9, Matthias Hebrok2, Tsutomu Chiba1,10, Hiroshi Seno1.
Abstract
Chromatin remodeler Brahma related gene 1 (BRG1) is silenced in approximately 10% of human pancreatic ductal adenocarcinomas (PDAs). We previously showed that BRG1 inhibits the formation of intraductal pancreatic mucinous neoplasm (IPMN) and that IPMN-derived PDA originated from ductal cells. However, the role of BRG1 in pancreatic intraepithelial neoplasia-derived (PanIN-derived) PDA that originated from acinar cells remains elusive. Here, we found that exclusive elimination of Brg1 in acinar cells of Ptf1a-CreER; KrasG12D; Brg1fl/fl mice impaired the formation of acinar-to-ductal metaplasia (ADM) and PanIN independently of p53 mutation, while PDA formation was inhibited in the presence of p53 mutation. BRG1 bound to regions of the Sox9 promoter to regulate its expression and was critical for recruitment of upstream regulators, including PDX1, to the Sox9 promoter and enhancer in acinar cells. SOX9 expression was downregulated in BRG1-depleted ADMs/PanINs. Notably, Sox9 overexpression canceled this PanIN-attenuated phenotype in KBC mice. Furthermore, Brg1 deletion in established PanIN by using a dual recombinase system resulted in regression of the lesions in mice. Finally, BRG1 expression correlated with SOX9 expression in human PDAs. In summary, BRG1 is critical for PanIN initiation and progression through positive regulation of SOX9. Thus, the BRG1/SOX9 axis is a potential target for PanIN-derived PDA.Entities:
Keywords: Cancer; Epigenetics; Gastroenterology; Mouse models; Oncology
Mesh:
Substances:
Year: 2018 PMID: 30010625 PMCID: PMC6063489 DOI: 10.1172/JCI94287
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808